Oral superparamagnetic particles for magnetic resonance imaging

Lönnemark, Maria; Hemmingsson, Anders; Ericsson, Anders; Gundersen, H. G.; Bach-Gansmo, T.

doi:10.3109/02841859009171997

Cited by 3 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, in some bowel loops there was no contrast agent while in others OMP was highly concentrated. The inhomogeneous distribution of OMP also created susceptibility artifacts due to a high concentration in some areas (13,16). This situation was obviously not satisfactory for the diagnostic purposes.…”

Section: Discussionmentioning

confidence: 99%

“…The physiochemical properties and the mechanism of action of this superparamagnetic compound have previously been described in detail (12,16). The active component of OMP consists of iron oxide particles of a ferrite type (size < 50 nm).…”

Section: Methodsmentioning

confidence: 99%

“…Oral magnetic particles (OMP, Nycomed) have been evaluated in preclinical and clinical studies and results from in vitro experiments, animal studies, and clinical trials (I, 8,[12][13][14][15][16]18) have already been published. The aims of the phase II trials were to evaluate safety, tolerability, and efficacy of OMP in patients with various abdominal pathologies.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Oral Magnetic Particles

Øksendal¹,

Bach-Gansmo²,

Jacobsen³

et al. 1993

Acta Radiol

Self Cite

View full text Add to dashboard Cite

Oral magnetic particles (OMP) have been evaluated in a clinical phase II trial program comprising 216 patients in 7 European centers. Adult patients referred for MR imaging for various abdominal pathologies were examined. The patients received OMP at a concentration of 0.1 gil (ultralow field) or 0.5 gil (mid/high field) and OMP was diluted in water or in a more viscous liquid formulation. Depending on the area of interest, OMP was ingested in a volume of 300 to 800 ml. OMP was well tolerated with no serious adverse events and the patient acceptability was good. OMP had a good contrast effect on all applied pulse sequences. The viscous formulation of OMP was homogeneously distributed through the entire gastrointestinal tract without inducing disturbing susceptibility artifacts. The postcontrast diagnostic information was improved in 70% of the cases. Based on the encouraging results in phase II, OMP has been advanced to phase III clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Oral Magnetic Particles

Øksendal¹,

Bach-Gansmo²,

Jacobsen³

et al. 1993

Acta Radiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The physiochemical properties and the mechanism of action of this superparamagnetic compound have previously been described in detail (12,16). The physiochemical properties and the mechanism of action of this superparamagnetic compound have previously been described in detail (12,16).…”

Section: Methodsmentioning

confidence: 99%

“…Oral magnetic particles (OMP, Nycomed) have been evaluated in preclinical and clinical studies and results from in vitro experiments, animal studies, and clinical trials (1, 8,[12][13][14][15][16]18) have already been published. The aims of the phase I1 trials were to evaluate safety, tolerability, and efficacy of OMP in patients with various abdominal pathologies.…”

mentioning

confidence: 99%

Oral Magnetic Particles

Øksendal¹,

Bach-Gansmo²,

Jacobsen³

et al. 1993

Acta Radiol

Self Cite

View full text Add to dashboard Cite

Oral magnetic particles (OMP) have been evaluated in a clinical phase 11 trial program comprising 216 patients in 7 European centers. Adult patients referred for MR imaging for various abdominal pathologies were examined. The patients received OMP at a concentration of 0.1 g/l (ultralow field) or 0.5 g/l (mid/high field) and OMP was diluted in water or in a more viscous liquid formulation. Depending on the area of interest, OMP was ingested in a volume of 300 to 800 ml. OMP was well tolerated with no serious adverse events and the patient acceptability was good. OMP had a good contrast effect on all applied pulse sequences. The viscous formulation of OMP was homogeneously distributed through the entire gastrointestinal tract without inducing disturbing susceptibility artifacts. The postcontrast diagnostic information was improved in 70% of the cases. Based on the encouraging results in phase 11, OMP has been advanced to phase 111 clinical trials.

show abstract